Volume : 10
Issue : 2
A report on the outcome of topical mitomycin C as the primary treatment for ocular surface squamous neoplasia
Hegde SS, Pooja GS, Prakash DN, Dharwadkar S
Pdf Page Numbers :- 82-86
Shubhratha S Hegde1,*, Pooja GS1, Prakash DN1 and Sandhya Dharwadkar1
1Department of Ophthalmology, Mysore Medical College & Research Institute, Irwin Road, Mysore 570001, Karnataka, India
*Corresponding author: Dr. Shubhratha S Hegde, Department Of Ophthalmology, Mysore Medical College & Research Institute, Irwin Road, Mysore-570001, Karnataka, India. Tel.: +919900566118; Email: email@example.com
Received 5 January 2022; Revised 7 March 2022; Accepted 14 March 2022; Published 22 March 2022
Citation: Hegde SS, Pooja GS, Prakash DN, Dharwadkar S. A report on the outcome of topical mitomycin C as the primary treatment for ocular surface squamous neoplasia. J Med Sci Res. 2022; 10(2):82-86. DOI: http://dx.doi.org/10.17727/JMSR.2022/10-16
Copyright: © 2022 Hegde SS et al. Published by KIMS Foundation and Research Center. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
View Full Text
Background: Although surgical excision is still the gold standard treatment for ocular surface squamous neoplasia (OSSN), interest in conservative medical approaches is steadily growing due to its advantages. The clinical outcome of topical mitomycin C (MMC) as the primary treatment for OSSN was reported. The primary outcome measure was clinical regression of the tumour. The secondary Outcome measures were duration of treatment, possible side effects and recurrences.
Materials and methods: In this prospective study 11 patients with the diagnosis of OSSN were included. All were treated with mitomycin C eye drops 0.02% 4 times daily for 4 days a week. The study was conducted at Mysore Medical College & Research Institute, Mysore for a period of 6 months from August 2020 to January 2021.
Results: Out of the 11 patients, complete tumour regression was achieved in 6 (54.5%) patients. The remaining 5 patients reported partial tumour regression. Mean duration of treatment was 6 weeks. The most common side effect noted was eye irritation. The side effect was transient and resolved with the cessation of treatment. No recurrence was observed during the follow up.
Conclusion: Topical chemotherapy can be tried as primary treatment in all patients with OSSN as it can cause complete or partial tumour regression with negligible side effects.
Keywords: ocular surface squamous neoplasia; mytomycin C; tumour regression